

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYCHOPO Page 1 of 3

(Induction Cycle 1)

DOCTOR'S ORDERS	Ht	cm	Wt	kg	BSA_	m²
REMINDER: Please ensure drug allerg	jies and previous	bleomyc	in are d	ocumented	on the	Allergy & Alert Form
	To be given:			Сус	le #:	
Date of Previous Cycle:						
☐ Delay treatment week(s) ☐ CBC & Diff day of treatment						
May proceed with doses as written if with than or equal to 80 x 10 ⁹ /L	in 96 hours ANC <u>g</u>	reater th	an or eq	<u>ıual to</u> 0.8 x	10 ⁹ /L a	and platelets greater
Dose modification for: Hematolog	y 🗌 Other	Toxicity				
Proceed with treatment based on bloo	d work from					
PREMEDICATIONS: Patient to take o	wn supply <mark>of oral m</mark>	nedication	ıs. RN/P	harmacist to	confirm	n
<u>Day 1:</u> PREMEDICATIONS FOR DOXOrubicin,	, vinCRIStine, and	cycloph	ospham	nide:		
dexamethasone 🗌 8 mg or 🔲 12 m	g (select one) PO	30 to 60 r	ninutes բ	orior to treat	ment.	
and select ONE of the following:						
ondansetron 8 mg PO 30 to	o 60 minutes prior t	o treatme	∍nt			
aprepitant 125 mg PO 30 to	o 60 minutes prior t	o treatme	ent			
ondansetron 8 mg PO 30 to	o 60 minutes prior t	o treatme	ent			
netupitant-palonosetron 30	00 mg-0.5 mg PO	30 to 60 ı	ninutes	prior to treat	ment	
hydrocortisone 100 mg IV prior t	o etoposide					
diphenhydrAMINE 50 mg IV prior	r to etoposide					
<u>Day 2:</u> PREMEDICATIONS FOR oBINutuzuma	b INFUSION:					
60 minutes prior to infusion: dexamet l	hasone 20 mg IV					
30 minutes prior to infusion: acetamin	ophen 650 to 975	mg PO a	ind diph	enhydrAMI	NE 50 r	mg PO
<u>Day 8 and Day 15:</u> PREMEDICATIONS FOR oBINutuzuma	b INFUSION:					
☐ If reaction to previous oBINutuzum Day 1, then 60 minutes prior to infusio				unt greater t	han 25	x 10 ⁹ /L before Cycle 1
30 minutes prior to infusion: acetamin	ophen 650 to 975	mg PO a	nd diphe	enhydrAMIN	1E 50 n	ng PO
☐ Other:						
DOCTOR'S SIGNATURE:						SIGNATURE:
						UC:



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYCHOPO Page 2 of 3 (Induction Cycle 1)

Date:					
** Have Hypersensitivity Reaction Tray and Protocol Available	**				
TREATMENT:					
Days 1 to 5:					
predniSONE 45 mg/m² x BSA =mg PO daily in AM on Days 1 to 5. (Round	d dose to nearest 25 mg)				
Day 1:					
DOXOrubicin 50 mg/m² x BSA =mg					
☐ Dose Modification:% =mg/m² x BSA = mg					
IV push on Day 1 .					
vinCRIStine 1.4 mg/m² x BSA =mg Dose Modification:% =mg/m² x BSA =mg					
☐ Dose Modification:% =mg/m² x BSA =mg IV in 50 mL NS over 15 minutes on Day 1 .					
cyclophosphamide 750 mg/m² x BSA =mg					
☐ Dose Modification:% =mg/m² x BSA = mg					
IV in 100 to 250 mL NS over 20 minutes to 1 hour on Day 1 .					
If cardiac dysfunction:					
Omit DOXOrubicin .					
Give etoposide 50 mg/m² x BSA =mg					
☐ Dose Modification: % = mg/m² x BSA = mg					
IV in 250 to 500 mL (non-DEHP bag) NS over 45 minutes on Day 1 (Use non-DEHP tub	•				
etoposide 100 mg/m² x BSA x (%) =mg PO on Days 2 and	I 3 (Round dose to nearest				
50 mg)					
If total bilirubin greater than 85 micromol/L:					
Omit DOXOrubicin .					
Change cyclophosphamide to 1100 mg/m² x BSA =mg					
Dose Modification:% =mg/m² x BSA =mg					
IV in 100 to 250 mL NS over 20 minutes to 1 hour on Day 1 .					
Day 2:					
oBINutuzumab 1000 mg IV in 250 mL NS on Day 2. Start infusion at 50 mg/h; after 30 minutes, increase by 50 mg/h every 30 minutes until rate	a = 400 mg/h unlaga taviaity				
occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table.	e – 400 mg/m unless toxicity				
For first dose, constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic.					
If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any					
existing symptoms occur, stop infusion and page physician.	•				
Days 8 and 15:					
oBINutuzumab 1000 mg IV in 250 mL NS on Days 8 and 15.					
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusior: Start infusion at 100 mg/h for 30 minutes; if tolerated, may escalate rate in increme minutes until rate = 400 mg/h. Refer to protocol appendix for oBINutuzumab infusion rate	nts of 100 mg/h every 30				
DOCTOR'S SIGNATURE:	SIGNATURE:				
	uc.				
	UC:				



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYCHOPO Page 3 of 3 (Induction Cycle 1)

Date:				
RETURN APPOINTMENT ORDERS				
Return in <u>three</u> weeks for Doctor and Cycle 2. Book <u>treatment</u> for Day 1 only.				
CBC & Diff prior to Day 1 of cycle 2 If clinically indicated: creatinine ALT total bilirubin HBV viral load Other tests:				
☐ Consults:☐ See general orders sheet for additional requests.				
DOCTOR'S SIGNATURE:	SIGNATURE:			
POULOU O CICIAL ONE				
	UC:			